Literature DB >> 2951427

Generation of suppressor cells in atopic patients during immunotherapy that modulate IgE synthesis.

R Tamir, J M Castracane, R E Rocklin.   

Abstract

We prospectively studied the effect of ragweed immunotherapy on the generation of suppressor T cells that modulate total and antiragweed IgE production in five patients with seasonal allergic rhinitis. Suppressor T cell depletion was accomplished by treating mononuclear cells (MNCs) with the monoclonal antibody Leu 2b followed by the addition of complement. Treated and untreated MNCs were obtained before and during (6 to 24 months) immunotherapy and were cultured at 1 X 10(6) cells per milliliter for 7 days in RPM1-1640 containing 10% fetal calf serum. In order to determine the effect of ragweed antigen on IgE production, untreated or Leu 2b-depleted MNCs were incubated with short ragweed extract (SRW) (1.0 to 10 micrograms/ml) for 20 hours, washed three times, and incubated for a further 6 days. The cell-free supernatants from each were harvested and assayed for total IgE by use of a modified PRIST assay. To determine specific IgE, a modified RAST procedure was used. Total or antiragweed IgE production was calculated by subtracting preformed IgE from the total or specific IgE content in the supernatant. Depletion of Leu 2-positive cells did not affect total IgE production before immunotherapy. In contrast, a statistically significant increase was observed in total IgE 6 months (p less than 0.05) and 13 months (p = 0.005) after immunotherapy. Specific antiragweed IgE production at these times was also enhanced, but this increase did not reach statistical significance. Before immunotherapy was begun, preincubation of MNCs with SRW did not change the amount of total IgE produced.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2951427     DOI: 10.1016/s0091-6749(87)80154-9

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  9 in total

Review 1.  Allergen immunotherapy. When is it useful?

Authors:  R H Loblay
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

Review 2.  Current status of allergen immunotherapy (hyposensitization): memorandum from a WHO/IUIS meeting.

Authors: 
Journal:  Bull World Health Organ       Date:  1989       Impact factor: 9.408

3.  Lymphocyte-mediated regulation of platelet activation during desensitization in patients with hymenoptera venom hypersensitivity.

Authors:  E Ledru; J Pestel; A Tsicopoulos; M Joseph; B Wallaert; A B Tonnel; A Capron
Journal:  Clin Exp Immunol       Date:  1988-08       Impact factor: 4.330

Review 4.  Immunological response to immunotherapy for immediate hypersensitivity: clinical relevance.

Authors:  R Tamir; A I Pick
Journal:  Immunol Res       Date:  1988       Impact factor: 2.829

5.  Venom immunotherapy modulates interleukin-4 and interferon-gamma messenger RNA expression of peripheral T lymphocytes.

Authors:  H Akoum; A Tsicopoulos; H Vorng; B Wallaert; J P Dessaint; M Joseph; Q Hamid; A B Tonnel
Journal:  Immunology       Date:  1996-04       Impact factor: 7.397

6.  Tracking antigen-specific T-cells during clinical tolerance induction in humans.

Authors:  Aamir Aslam; Hsien Chan; David A Warrell; Siraj Misbah; Graham S Ogg
Journal:  PLoS One       Date:  2010-06-09       Impact factor: 3.240

7.  Decreased production of CD8 (T8) antigen after immunotherapy.

Authors:  K H Hsieh
Journal:  J Clin Immunol       Date:  1989-03       Impact factor: 8.317

8.  Detection of auto-anti-idiotypic antibodies to Lol p I (rye I) IgE antibodies in human sera by the use of murine idiotypes: levels in atopic and non-atopic subjects and effects of immunotherapy.

Authors:  J Hébert; D Bernier; W Mourad
Journal:  Clin Exp Immunol       Date:  1990-06       Impact factor: 4.330

9.  The effect of rush immunotherapy with house dust mite in the production of IL-5 and IFN-gamma from the peripheral blood T cells of asthmatic children.

Authors:  Hyo-Bin Kim; Hyun-Seung Jin; So-Yeon Lee; Ja-Hyeong Kim; Bong-Seong Kim; Seong Jong Park; Soo-Jong Hong
Journal:  J Korean Med Sci       Date:  2009-06-12       Impact factor: 2.153

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.